Press Releases

Date Title and Summary Additional Formats
Toggle Summary ArQule Announces $9.5 Million Private Placement of Preferred Stock
The Pontifax Group led this financing with additional participation from an Israeli-based healthcare equity fund Ran Nussbaum , Managing Partner and co-founder of The Pontifax Group , joins ArQule Board BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule, Inc.
View HTML
Toggle Summary FDA Grants Rare Pediatric Disease Designation to ArQule's Miransertib (ARQ 092) for the Treatment of Proteus Syndrome
BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to miransertib (ARQ 092) for the treatment of Proteus syndrome. Under the FDA's rare pediatric disease priority review
View HTML
Toggle Summary ArQule To Report Third Quarter 2017 Financial Results On November 9, 2017
BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule , Inc. (Nasdaq: ARQL) today announced it will report financial results for the third quarter 2017 before the market opens on Thursday, November 9, 2017 . The Company will hold a conference call and webcast on the same day at 9:00 a.m.
View HTML
Toggle Summary ArQule Announces $15.7 Million Private Placement of Common Stock
Company also raises approximately $4M through unrelated business development activities and other sources during September-October BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule, Inc. (NASDAQ: ARQL) today announced the closing of a private placement with certain institutional investors, with leading
View HTML
Toggle Summary ArQule to Present at the Cantor Fitzgerald Global Healthcare Conference on September 26, 2017
BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci , Chief Executive Officer, and Dr. Brian Schwartz , M.D., Head of Research and Development and Chief Medical Officer, will present at the Cantor Fitzgerald Global Healthcare Conference on September 26
View HTML
Toggle Summary ArQule Reports Second Quarter 2017 Financial Results
Conference call scheduled today at 9:00 a.m. ET BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule , Inc. (Nasdaq: ARQL) today announced its financial results for the second quarter of 2017. For the quarter ended June 30, 2017 , the Company reported a net loss of $7,201,000 or $0.10 per share, compared
View HTML
Toggle Summary ArQule To Report Second Quarter 2017 Financial Results On August 4, 2017
BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule , Inc. (Nasdaq: ARQL) today announced it will report financial results for the second quarter 2017 before the market opens on Friday, August 4, 2017 . The Company will hold a conference call and webcast on the same day at 9:00 a.m.
View HTML
Toggle Summary ArQule Announces First Patient Dosed in Phase 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignancies
Trial is enrolling patients refractory to standard of care, including ibrutinib BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that the first patient has been dosed in a phase 1a/b trial with its BTK inhibitor, ARQ 531, in patients with B-cell malignancies
View HTML
Toggle Summary ArQule Presents Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association (EHA)
In preclinical models ARQ 531 demonstrates potent anti-tumor activity in DLBCL BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that preclinical data for ARQ 531 in diffuse large B-cell lymphoma (DLBCL) in vitro and in vivo tumor models was presented at EHA Congress
View HTML
Toggle Summary ArQule Announces First Patient Dosed in Company Sponsored Phase 1/2 Trial of AKT Inhibitor, ARQ 092, for Rare Overgrowth Diseases
Trial will enroll patients with Overgrowth Diseases driven by the PI3K/AKT1 pathway BURLINGTON, Mass. --(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that the first patient has been dosed in a company sponsored phase 1/2 trial with its AKT inhibitor, ARQ 092, in patients with
View HTML

Questions or Concerns?

Please feel free to contact by one of the methods below

Online Form   Call (781) 994-0300

These archived presentations and related materials are provided for reference by ArQule, Inc. Information contained in the materials was current only as of the date of the event. ArQule, Inc. does not update or delete outdated information contained in these materials, and it expressly disclaims any obligation to do so. The materials are property of ArQule, Inc. and any use, dissemination or republication of the files is prohibited without the express written consent of ArQule, Inc.